VHT240816C245000
- 28.28
- 0.000.00%
Vanguard Health Care ETF Newsroom
Centene Downgraded at Jefferies Amid Higher Medicaid Utilization
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Danaher Price Target Raised to $310.00/Share From $290.00 by TD Cowen
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $120 From $125
BofA Securities Maintains Danaher(DHR.US) With Hold Rating, Maintains Target Price $275
Stifel Adjusts Price Target on Danaher to $250 From $235
A Quick Look at Today's Ratings for Danaher(DHR.US), With a Forecast Between $270 to $310
Danaher Analyst Ratings
RBC Raises Price Target on Danaher to $300 From $297, Keeps Outperform Rating
RBC Capital Remains a Buy on Danaher (DHR)
Cantor Fitzgerald Maintains UnitedHealth(UNH.US) With Buy Rating, Maintains Target Price $591
UnitedHealth Group Analyst Ratings
Evercore ISI Adjusts Price Target on Danaher to $275 From $260, Maintains Outperform Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $190
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Johnson & Johnson Analyst Ratings
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com